HOHL BENJAMIN (CHIEF FINANCIAL OFFICER) sold 16.4% of their position (10K shares) of ENLIVEN THERAPEUTICS, INC. on the open market
Open‑market sale worth $295.8K — a significant reduction. Review remaining holdings and any 10b5‑1 plan disclosures.
S · 1 sale
Filed: 3/10/2026ACC: 0001882764-26-000002
Officer· CHIEF FINANCIAL OFFICER
Since Feb 2026
-10K
Net shares
Net seller
$295.8K
Total sold
1
Open market trades
0B · 1S
1
Total transactions
10K disposed
Non-Derivative Transactions1
Common Stock
Direct
Shares
−10K
Price / share
$29.58
Trade value
$295.84K
% of position
16.4%
3/6/2026
61K→51K
Total
Net shares
−10K
Net value
-$295.84K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 3/6/2026 | S · Sale | −10K | $29.58 | $295.84K | 16.4% | 61K | 51K |
| Total | −10K | -$295.84K | ||||||
Derivative Transactions0
No derivative transactions reported